| PRECLINICAL | evidence | In brief: Removal of suicidality warning from GLP-1 Agonists for weight management. | Wegovy | — | 2026-02-16 |
| PRECLINICAL | evidence | A Narrative Review on GLP-1 Receptor Agonists for Obesity in Older Women: Maximizing Weight Loss While Preserving Lean Mass. | Semaglutide | — | 2026-02-14 |
| PRECLINICAL | evidence | Wegovy: FDA accuses Novo Nordisk of "false or misleading" ad for weight loss pill. | Wegovy | — | 2026-02-13 |
| PRECLINICAL | evidence | Clinical Impact of Semaglutide Beyond Glycemic Control: A Critical Analysis of Oncogenic Potential and Mitigation of Cardiotoxicity. | Semaglutide | — | 2026-02-10 |
| PRECLINICAL | evidence | GLP-1 drugs: New eyesight warning for Ozempic/Wegovy. | Ozempic | — | 2026-02-06 |
| PRECLINICAL | evidence | Bridging Innovation and Practice in Type 2 Diabetes Mellitus: Novel Antidiabetic Therapies and the Expanding Role of Community Pharmacists. | Semaglutide | — | 2026-02-05 |
| PRECLINICAL | evidence | Oral semaglutide (Wegovy) for weight loss. | Wegovy | — | 2026-02-02 |
| PRECLINICAL | evidence | Identification of semaglutide use through detection of U6 and U7 metabolites in human urine. | Ozempic | — | 2026-02-01 |
| PRECLINICAL | evidence | National Consensus on Semaglutide in Cardiology: From Clinical Evidence to Clinical Translation. | Semaglutide | — | 2026-02-01 |
| PRECLINICAL | evidence | The Risk of Aspiration Is Low With Continuing Semaglutide During Elective Eye Surgery When Patients Receive Only Moderate Sedation. | Ozempic | — | 2026-02-01 |
| PRECLINICAL | evidence | Emergence of "ozempic face": addressing unintended consequences of rapid weight loss. | Ozempic | — | 2026-02-01 |
| PRECLINICAL | evidence | Weight Regain After GLP-1-Based Therapy Discontinuation: Failure, Physiology, or Follow-Up Gap. | Semaglutide | — | 2026-02-01 |
| PRECLINICAL | evidence | Comparative Analysis of Efficacy and Safety of the Glucagon-Like-Peptide-1 Receptor Agonists Tirzepatide and Semaglutide in Solid-Organ Transplant Recipients. | Semaglutide | Glycemic control | 2026-02-01 |
| PRECLINICAL | evidence | A Rare Case of Semaglutide-Associated Small Bowel Obstruction Complicated by Acute Kidney Injury Requiring Dialysis. | Semaglutide | — | 2026-02-01 |
| PRECLINICAL | evidence | The Therapeutic Potential of Glucagon-Like Peptide-1 Receptor Agonists in Psoriasis and Hidradenitis Suppurativa. | Semaglutide | — | 2026-02-01 |
| PRECLINICAL | evidence | Liver benefits of early initiation of low-dose GLP-1 receptor agonists in newly diagnosed type 2 diabetes - A case report. | Semaglutide | — | 2026-02-01 |
| PRECLINICAL | evidence | Effect of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists and Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitors on Atherosclerotic Cardiovascular Risk Among Patients With Type 2 Diabetes in Primary Health Care Settings in Jeddah, Saudi Arabia. | Semaglutide | — | 2026-02-01 |
| PRECLINICAL | evidence | Prevalence and Factors Associated with GLP-1 Receptor Agonist Use for Weight Management Among Overweight and Obese Adults in the Eastern Province of Saudi Arabia. | Ozempic | — | 2026-01-29 |
| PRECLINICAL | evidence | Electronic word-of-mouth and off-label use of Ozempic and other GLP-1 medications. | Ozempic | — | 2026-01-28 |
| PRECLINICAL | evidence | What is "triple strength" Wegovy, and why has the MHRA approved it? | Wegovy | — | 2026-01-19 |
| PRECLINICAL | evidence | Prevalence and Predictors of Hair Shedding among GLP-1 Receptor Agonist Users: A Cross-Sectional Study from Saudi Arabia. | Semaglutide | — | 2026-01-19 |
| PRECLINICAL | evidence | The ethics of wegovy for children: the argument from too many unknowns. | Wegovy | — | 2026-01-17 |
| PRECLINICAL | evidence | Patient Perceptions of Ozempic (Semaglutide) for Weight Loss: Mixed Methods Analysis of Online Medication Reviews. | Ozempic | Weight & fat loss | 2026-01-09 |
| PRECLINICAL | evidence | Prevalence of use and interest in using glucagon-like peptide-1 receptor agonists for weight loss: a population study in Great Britain. | Ozempic | — | 2026-01-08 |
| PRECLINICAL | evidence | Ethical considerations for semaglutide use in children. | Ozempic | — | 2026-01-06 |
| PRECLINICAL | evidence | Metabolic and nutritional stress-associated dilated cardiomyopathy in the setting of semaglutide use and long-term nicotine replacement therapy: a case report and literature review. | Semaglutide | — | 2026-01-01 |
| PRECLINICAL | evidence | Disruptions in Aesthetic Medicine: A Global Analysis of GLP-1 Agonists Using Punctuated Equilibrium Framework. | Ozempic | Skin appearance & aging | 2026-01-01 |
| PRECLINICAL | evidence | Misrepresentation of semaglutide in social media. | Ozempic | Weight & fat loss | 2026-01-01 |
| PRECLINICAL | evidence | Semaglutide. | Ozempic | — | 2026-01-01 |
| PRECLINICAL | evidence | Deep Venous Thrombosis Within Two Weeks of Initiating Oral Semaglutide (Rybelsus): A Case Report. | Rybelsus | — | 2026-01-01 |
| PRECLINICAL | evidence | Decreased risk of post-thyroidectomy hypocalcemia with history of GLP-1RA use. | Ozempic | — | 2026-01-01 |
| PRECLINICAL | evidence | Rising Public Interest in Weight Loss Medications and Growing Awareness of Their Aesthetic Sequelae: An Infodemiologic Google Trends Analysis and Clinical Diagnostic Patterning. | Ozempic | Weight & fat loss | 2026-01-01 |
| PRECLINICAL | evidence | Semaglutide-Induced Atypical Pustular Drug Eruption: A Case Report. | Ozempic | — | 2026-01-01 |
| PRECLINICAL | evidence | Response by Sharp to ""Ozempic Face": Construct, Consequence, or Clinical Entity?" by Daneshgaran et al. | Ozempic | — | 2026-01-01 |
| PRECLINICAL | evidence | Evaluating Semaglutide's Protection in H/R - Injured AC16 Cardiomyocytes: Oxidative Stress, Inflammation, Apoptosis, and Autophagy Insights. | Semaglutide | — | 2026-01-01 |
| PRECLINICAL | evidence | GLP-1 receptor agonist-associated eosinophilic duodenitis presenting as a bowel obstruction : a case report and literature review. | Semaglutide | — | 2026-01-01 |
| PRECLINICAL | evidence | Semaglutide and tirzepatide: Oral cavity effects of weight-loss therapies. | Semaglutide | — | 2026-01-01 |
| PRECLINICAL | evidence | Investigating the Link Between Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists and Non-arteritic Ischemic Optic Neuropathy: A Case Report of Semaglutide-Induced Optic Neuropathy. | Semaglutide | — | 2026-01-01 |
| PRECLINICAL | evidence | A Bibliometric Analysis Review of the Top 50 Most Cited Articles on Incretin-Based Therapy for Weight Reduction and Diabetes Management. | Semaglutide | — | 2026-01-01 |
| PRECLINICAL | evidence | Euglycemic Ketoacidosis Following the Use of Counterfeit Semaglutide for Weight Loss. | Semaglutide | — | 2026-01-01 |
| PRECLINICAL | evidence | The association between glucagon-like peptide-1 receptor agonist and rheumatoid arthritis: a population-based case-control study. | Semaglutide | — | 2026-01-01 |
| PRECLINICAL | evidence | Post-sleeve gastrectomy weight loss: Role of botulinum toxin and semaglutide injections. | Semaglutide | — | 2026-01-01 |
| PRECLINICAL | evidence | Real-world effectiveness, safety, and quality of life of biosynthetic semaglutide in Pakistani adults with type 2 diabetes mellitus: a study protocol. | Semaglutide | — | 2026-01-01 |
| PRECLINICAL | evidence | Glucagon-like peptide-1 agonists in children with obesity and type 2 diabetes. an umbrella review. | Semaglutide | Glycemic control | 2026-01-01 |
| PRECLINICAL | evidence | Community Pharmacists' Knowledge and Counseling Competence on GLP-1 Receptor Agonists in Obesity and Type 2 Diabetes Care in Turkiye: A Cross-Sectional Study. | Semaglutide | — | 2026-01-01 |
| PRECLINICAL | evidence | Trends and projections of overweight and obesity among midlife women in the United States, 1990-2050: A sub‑study of the Global Burden of Disease 2021. | Semaglutide | Weight & fat loss | 2026-01-01 |
| PRECLINICAL | evidence | Clinical Insights into the Pathogenesis and Treatment Strategies of Acanthosis Nigricans: A Bibliometric Study of Current Trends and Future Directions. | Semaglutide | — | 2026-01-01 |
| PRECLINICAL | evidence | A Systematic Review and Meta-Analysis of Efficacy and Safety of Liraglutide in Patients with Type 2 Diabetes Mellitus. | Semaglutide | — | 2026-01-01 |
| PRECLINICAL | evidence | Do no harm: managing nausea and vomiting in GLP-1 based obesity therapies. | Semaglutide | — | 2026-01-01 |
| PRECLINICAL | evidence | Periconceptional GLP-1 receptor agonist exposure and obstetric outcomes: a Danish nationwide cohort study. | Semaglutide | — | 2026-01-01 |